Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorIcahn School of Medicine at Mount Sinai

About this trial

This will be a pilot multi-arm clinical trial investigating the feasibility of Lumbrokinase (LK) as an intervention in three clinical cohorts:

* Long Covid (LC) * Post-treatment Lyme disease syndrome (PTLDS) * Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Any gender

Aged 18+

Baseline EQ-VAS ≤70; EQ-VAS before the index infection ≥80 (this information is collected as part of the baseline survey).

Long Covid

Disqualifiers

Current use of antiplatelet or anticoagulation regimen

Diagnosis of an autoimmune condition such as Chronic EBV, Multiple Sclerosis, Hashimoto's Disease, etc. which would impact the immunological profiling analysis.

Pregnancy or lactation

Known allergy to earthworms (Lumbrokinase is a supplement that is derived from earthworms)

Trial design

Design model

Parallel

Treatments tested in this trial

  • Lumbrokinase

    Dietary supplement

    Boluoke® brand lumbrokinase capsules will be taken daily for 6 weeks.

Treatment groups

120 Participants
are divided into 3 treatment groups
Group A: Long CovidExperimental treatment 1 intervention
Group B: Post-treatment Lyme Disease SyndromeExperimental treatment 1 intervention
Group C: Myalgic Encephalomyelitis/Chronic Fatigue SyndromeExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

EuroQol Visual Analogue Scale Score (EQ-VAS)

The EQ VAS is a visual analogue scale that allows individuals to rate their overall health from 0 (worst imaginable health) to 100 (best imaginable health), providing a quantitative measure of health as judged by the patient.

Time frame
Up to 12 weeks

Secondary outcomes

1

The EuroQol Five-Dimensional Health Questionnaire (EQ-5D-5L)

The EQ-5D-5L is a validated, standardized, generic instrument that is a preference-based health- related quality of life questionnaire. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate their health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. Full scale from 5 to 25, with higher score indicating poorer health outcomes.

Time frame
Up to 12 weeks
2

10-Meter Walk Test

The scoring for the 10-meter walk test involves recording the time it takes to walk 10 meters and then calculating walking speed in meters per second (m/s). The test typically measures the time it takes to walk the middle 6 meters of a 10-meter walk, allowing for acceleration and deceleration.

Time frame
Up to 12 weeks
3

Root mean square of successive differences between normal heartbeats (RMSSD)

The RMSSD is obtained by first calculating each successive time difference between heartbeats in ms. Then, each of the values is squared and the result is averaged before the square root of the total is obtained. This is a measure of parasympathetic nervous system function. Higher RMSSD values generally indicate greater parasympathetic activity and a more resilient heart.

Time frame
Up to 12 weeks
4

BrainCheck Cognitive Assessment Battery

The BrainCheck software is an advanced digital cognitive assessment completed on a computer or tablet. Scores within one standard deviation of the mean are considered normal, while scores outside this range may suggest cognitive impairment.

Time frame
Up to 12 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Icahn School of Medicine at Mount Sinai

Lead sponsor

Columbia University

Collaborator

PolyBio Research Foundation

Collaborator